Estimates Revisions Nykode Therapeutics OTC Markets
Stocks
VACBF
NO0010714785
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3213 USD | -1.05% |
|
-1.05% | +106.23% |
| 05-27 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 05-27 | Nykode Therapeutics AS, Q1 2026 Earnings Call, May 27, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- VACC Stock
- VACBF Stock
- Consensus Nykode Therapeutics
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
